← Leaderboards
Fang Li
Duke University
$1,938,270
Attributed
$4,012,008
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,012,008 · 4
By mechanism
R01$4,012,008 · 4
Top collaborators
- Yunyan Jennifer Jennifer Zhang6 shared
- Scott J Antonia3 shared
- Xiaoping Zhong3 shared
Most similar at Duke University
Same institution · by research overlap
- Michael Barry Kastan$65,974,699
- Michael Rod Zalutsky$18,420,913
- Darell D Bigner$25,397,506
- John H Sampson$43,413,436
- Chuan-Yuan Li$14,248,346
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularNeoplastic CellMediatingPlayCancer TherapyRadiation TherapyTumorResponseInsightCheckpoint TherapyT-LymphocyteTumor GrowthImmuneAntibodiesTumor ImmunityInhibitorImmunotherapyInterferon Type IPathway InteractionsSynergismImmune Cell InfiltrateRestraintImmune Checkpoint BlockadeSignal Pathway
Grant awards (8)
Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy$535,077
R01 · FY2025 · CA
Targeting ATM to boost systemic effects of radiotherapy and immunotherapy$526,563
R01 · FY2025 · CA
Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy$508,324
R01 · FY2024 · CA
Targeting ATM to boost systemic effects of radiotherapy and immunotherapy$500,236
R01 · FY2024 · CA
Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy$524,375
R01 · FY2023 · CA
Targeting ATM to boost systemic effects of radiotherapy and immunotherapy$516,032
R01 · FY2023 · CA
Targeting apoptotic caspases to enhance cancer radiotherapy$458,400
R01 · FY2022 · CA · contact PI
Necroptotic genes in cancer cellular response to radiation$443,001
R01 · FY2021 · CA · contact PI